[1]
|
Sugimoto, M.A., Vago, J.P., Perretti, M. and Teixeira, M.M. (2019) Mediators of the Resolution of the Inflammatory Response. Trends in Immunology, 40, 212-227. https://doi.org/10.1016/j.it.2019.01.007
|
[2]
|
Perretti, M., Leroy, X., Bland, E.J. and Montero-Melendez, T. (2015) Resolution Pharmacology: Opportunities for Therapeutic Innovation in Inflammation. Trends in Pharmacological Sciences, 36, 737-755. https://doi.org/10.1016/j.tips.2015.07.007
|
[3]
|
Chiang, N., Fredman, G., Bäckhed, F., Oh, S.F., Vickery, T., Schmidt, B.A., et al. (2012) Infection Regulates Pro-Resolving Mediators that Lower Antibiotic Requirements. Nature, 484, 524-528. https://doi.org/10.1038/nature11042
|
[4]
|
Fullerton, J.N. and Gilroy, D.W. (2016) Resolution of Inflammation: A New Therapeutic Frontier. Nature Reviews Drug Discovery, 15, 551-567. https://doi.org/10.1038/nrd.2016.39
|
[5]
|
Quiros, M. and Nusrat, A. (2019) Saving Problematic Mucosae: SPMs in Intestinal Mucosal Inflammation and Repair. Trends in Molecular Medicine, 25, 124-135. https://doi.org/10.1016/j.molmed.2018.12.004
|
[6]
|
Radbakhsh, S., Katsiki, N., Santos, R.D., Mikhailidis, D.P., Mantzoros, C.S. and Sahebkar, A. (2022) Effects of Statins on Specialized Pro-Resolving Mediators: An Additional Pathway Leading to Resolution of Inflammation. Metabolism, 132, Article 155211. https://doi.org/10.1016/j.metabol.2022.155211
|
[7]
|
Le Berre, C., Honap, S. and Peyrin-Biroulet, L. (2023) Ulcerative Colitis. The Lancet, 402, 571-584. https://doi.org/10.1016/s0140-6736(23)00966-2
|
[8]
|
Jairath, V. and Feagan, B.G. (2020) Global Burden of Inflammatory Bowel Disease. The Lancet Gastroenterology & Hepatology, 5, 2-3. https://doi.org/10.1016/s2468-1253(19)30358-9
|
[9]
|
Al-Horani, R., Spanudakis, E. and Hamad, B. (2021) The Market for Ulcerative Colitis. Nature Reviews Drug Discovery, 21, 15-16. https://doi.org/10.1038/d41573-021-00194-5
|
[10]
|
Serhan, C.N. and Levy, B.D. (2018) Resolvins in Inflammation: Emergence of the Pro-Resolving Superfamily of Mediators. Journal of Clinical Investigation, 128, 2657-2669. https://doi.org/10.1172/jci97943
|
[11]
|
Serhan, C.N., Chiang, N., Dalli, J. and Levy, B.D. (2014) Lipid Mediators in the Resolution of Inflammation. Cold Spring Harbor Perspectives in Biology, 7, a016311. https://doi.org/10.1101/cshperspect.a016311
|
[12]
|
Pistorius, K., Souza, P.R., De Matteis, R., Austin-Williams, S., Primdahl, K.G., Vik, A., et al. (2018) PDn-3 DPA Pathway Regulates Human Monocyte Differentiation and Macrophage Function. Cell Chemical Biology, 25, 749-760. https://doi.org/10.1016/j.chembiol.2018.04.017
|
[13]
|
Gobbetti, T., Dalli, J., Colas, R.A., Federici Canova, D., Aursnes, M., Bonnet, D., et al. (2017) Protectin D1n-3 DPA and Resolvin D5n-3 DPA Are Effectors of Intestinal Protection. Proceedings of the National Academy of Sciences of the United States of America, 114, 3963-3968. https://doi.org/10.1073/pnas.1617290114
|
[14]
|
Campbell, E.L., MacManus, C.F., Kominsky, D.J., Keely, S., Glover, L.E., Bowers, B.E., et al. (2010) Resolvin E1-Induced Intestinal Alkaline Phosphatase Promotes Resolution of Inflammation through LPS Detoxification. Proceedings of the National Academy of Sciences of the United States of America, 107, 14298-14303. https://doi.org/10.1073/pnas.0914730107
|
[15]
|
Panigrahy, D., Gilligan, M.M., Serhan, C.N. and Kashfi, K. (2021) Resolution of Inflammation: An Organizing Principle in Biology and Medicine. Pharmacology & Therapeutics, 227, Article 107879. https://doi.org/10.1016/j.pharmthera.2021.107879
|
[16]
|
Wan, M., Godson, C., Guiry, P.J., Agerberth, B. and Haeggström, J.Z. (2011) Leukotriene B4/Antimicrobial Peptide LL-37 Proinflammatory Circuits Are Mediated by BLT1 and FPR2/ALX and Are Counterregulated by Lipoxin A4 and Resolvin E1. The FASEB Journal, 25, 1697-1705. https://doi.org/10.1096/fj.10-175687
|
[17]
|
Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J.N., Petasis, N.A., et al. (2005) Resolvin E1, an Endogenous Lipid Mediator Derived from Omega-3 Eicosapentaenoic Acid, Protects against 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis. Proceedings of the National Academy of Sciences of the United States of America, 102, 7671-7676. https://doi.org/10.1073/pnas.0409271102
|
[18]
|
Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C., Yang, R., et al. (2010) Resolvin D1 Binds Human Phagocytes with Evidence for Proresolving Receptors. Proceedings of the National Academy of Sciences of the United States of America, 107, 1660-1665. https://doi.org/10.1073/pnas.0907342107
|
[19]
|
Chiang, N., Dalli, J., Colas, R.A. and Serhan, C.N. (2015) Identification of Resolvin D2 Receptor Mediating Resolution of Infections and Organ Protection. Journal of Experimental Medicine, 212, 1203-1217. https://doi.org/10.1084/jem.20150225
|
[20]
|
Sun, Y., Oh, S.F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., et al. (2007) Resolvin D1 and Its Aspirin-Triggered 17R Epimer: Stereochemical Assignments, Anti-Inflammatory Properties, and Enzymatic Inactivation. Journal of Biological Chemistry, 282, 9323-9334. https://doi.org/10.1074/jbc.m609212200
|
[21]
|
Schmid, M., Gemperle, C., Rimann, N. and Hersberger, M. (2016) Resolvin D1 Polarizes Primary Human Macrophages toward a Proresolution Phenotype through GPR32. The Journal of Immunology, 196, 3429-3437. https://doi.org/10.4049/jimmunol.1501701
|
[22]
|
Lee, H.-N., Choi, Y.-S., Kim, S.H., Zhong, X., Kim, W., Park, J.S., et al. (2021) Resolvin D1 Suppresses Inflammation-Associated Tumorigenesis in the Colon by Inhibiting IL-6-Induced Mitotic Spindle Abnormality. The FASEB Journal, 35, e21432. https://doi.org/10.1096/fj.202002392r
|
[23]
|
Zeng, C., Liu, X., Zhu, S., Xiong, D., Zhu, L., Hou, X., et al. (2022) Resolvin D1 Ameliorates Hepatic Steatosis by Remodeling the Gut Microbiota and Restoring the Intestinal Barrier Integrity in DSS-Induced Chronic Colitis. International Immunopharmacology, 103, Article 108500. https://doi.org/10.1016/j.intimp.2021.108500
|
[24]
|
Campbell, E.L., Louis, N.A., Tomassetti, S.E., Canny, G.O., Arita, M., Serhan, C.N., et al. (2007) Resolvin E1 Promotes Mucosal Surface Clearance of Neutrophils: A New Paradigm for Inflammatory Resolution. The FASEB Journal, 21, 3162-3170. https://doi.org/10.1096/fj.07-8473com
|
[25]
|
Ishida, T., Yoshida, M., Arita, M., Nishitani, Y., Nishiumi, S., Masuda, A., et al. (2010) Resolvin E1, an Endogenous Lipid Mediator Derived from Eicosapentaenoic Acid, Prevents Dextran Sulfate Sodium-Induced Colitis. Inflammatory Bowel Diseases, 16, 87-95. https://doi.org/10.1002/ibd.21029
|
[26]
|
Quiros, M., Feier, D., Birkl, D., Agarwal, R., Zhou, D.W., García, A.J., et al. (2020) Resolvin E1 Is a Pro-Repair Molecule that Promotes Intestinal Epithelial Wound Healing. Proceedings of the National Academy of Sciences of the United States of America, 117, 9477-9482. https://doi.org/10.1073/pnas.1921335117
|
[27]
|
Chiang, N., Serhan, C.N., Dahlén, S., Drazen, J.M., Hay, D.W.P., Rovati, G.E., et al. (2006) The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in vivo. Pharmacological Reviews, 58, 463-487. https://doi.org/10.1124/pr.58.3.4
|
[28]
|
Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K. and Serhan, C.N. (2001) Lipid Mediator Class Switching during Acute Inflammation: Signals in Resolution. Nature Immunology, 2, 612-619. https://doi.org/10.1038/89759
|
[29]
|
Godson, C., Mitchell, S., Harvey, K., Petasis, N.A., Hogg, N. and Brady, H.R. (2000) Cutting Edge: Lipoxins Rapidly Stimulate Nonphlogistic Phagocytosis of Apoptotic Neutrophils by Monocyte-Derived Macrophages. The Journal of Immunology, 164, 1663-1667. https://doi.org/10.4049/jimmunol.164.4.1663
|
[30]
|
Gewirtz, A.T., Collier-Hyams, L.S., Young, A.N., Kucharzik, T., Guilford, W.J., Parkinson, J.F., et al. (2002) Lipoxin A4 Analogs Attenuate Induction of Intestinal Epithelial Proinflammatory Gene Expression and Reduce the Severity of Dextran Sodium Sulfate-Induced Colitis. The Journal of Immunology, 168, 5260-5267. https://doi.org/10.4049/jimmunol.168.10.5260
|
[31]
|
Vong, L., Ferraz, J.G.P., Dufton, N., Panaccione, R., Beck, P.L., Sherman, P.M., et al. (2012) Up-Regulation of Annexin-A1 and Lipoxin A4 in Individuals with Ulcerative Colitis May Promote Mucosal Homeostasis. PLOS ONE, 7, e39244. https://doi.org/10.1371/journal.pone.0039244
|
[32]
|
Ağış, E.R., Savaş, B. and Melli, M. (2015) Impact of Colonic Mucosal Lipoxin A4 Synthesis Capacity on Healing in Rats with Dextran Sodium Sulfate-Induced Colitis. Prostaglandins & Other Lipid Mediators, 121, 63-69. https://doi.org/10.1016/j.prostaglandins.2015.04.001
|
[33]
|
Serhan, C.N., Gotlinger, K., Hong, S., Lu, Y., Siegelman, J., Baer, T., et al. (2006) Anti-Inflammatory Actions of Neuroprotectin D1/Protectin D1 and Its Natural Stereoisomers: Assignments of Dihydroxy-Containing Docosatrienes. The Journal of Immunology, 176, 1848-1859. https://doi.org/10.4049/jimmunol.176.3.1848
|
[34]
|
Masterson, J.C., McNamee, E.N., Fillon, S.A., Hosford, L., Harris, R., Fernando, S.D., et al. (2014) Eosinophil-Mediated Signalling Attenuates Inflammatory Responses in Experimental Colitis. Gut, 64, 1236-1247. https://doi.org/10.1136/gutjnl-2014-306998
|
[35]
|
Serhan, C.N., Yang, R., Martinod, K., Kasuga, K., Pillai, P.S., Porter, T.F., et al. (2008) Maresins: Novel Macrophage Mediators with Potent Antiinflammatory and Proresolving Actions. Journal of Experimental Medicine, 206, 15-23. https://doi.org/10.1084/jem.20081880
|
[36]
|
Marcon, R., Bento, A.F., Dutra, R.C., Bicca, M.A., Leite, D.F.P. and Calixto, J.B. (2013) Maresin 1, a Proresolving Lipid Mediator Derived from Omega-3 Polyunsaturated Fatty Acids, Exerts Protective Actions in Murine Models of Colitis. The Journal of Immunology, 191, 4288-4298. https://doi.org/10.4049/jimmunol.1202743
|
[37]
|
Gu, Z., Lamont, G.J., Lamont, R.J., Uriarte, S.M., Wang, H. and Scott, D.A. (2016) Resolvin D1, Resolvin D2 and Maresin 1 Activate the GSK3β Anti-Inflammatory Axis in TLR4-Engaged Human Monocytes. Innate Immunity, 22, 186-195. https://doi.org/10.1177/1753425916628618
|
[38]
|
Wang, H., Shi, P., Huang, C., et al. (2016) Maresin 1 Ameliorates Iron-Deficient Anemia in IL-10(-/-) Mice with Spontaneous Colitis by the Inhibition of Hepcidin Expression though the IL-6/STAT3 Pathway. American Journal of Translational Research, 8, 2758-2766.
|
[39]
|
Miranda, J., Brazil, J.C., Morris, A.H., Parkos, C.A., Quiros, M. and Nusrat, A. (2023) Maresin-2 Promotes Mucosal Repair and Has Therapeutic Potential When Encapsulated in Thermostable Nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 120, e2218162120. https://doi.org/10.1073/pnas.2218162120
|
[40]
|
Chiang, N. and Serhan, C.N. (2020) Specialized Pro-Resolving Mediator Network: An Update on Production and Actions. Essays in Biochemistry, 64, 443-462. https://doi.org/10.1042/ebc20200018
|
[41]
|
Orr, S.K., Colas, R.A., Dalli, J., Chiang, N. and Serhan, C.N. (2015) Proresolving Actions of a New Resolvin D1 Analog Mimetic Qualifies as an Immunoresolvent. American Journal of Physiology-Lung Cellular and Molecular Physiology, 308, L904-L911. https://doi.org/10.1152/ajplung.00370.2014
|
[42]
|
Torricelli, A.A., Santhanam, A., Agrawal, V., et al. (2014) Resolvin E1 analog RX-10045 0.1% Reduces Corneal Stromal Haze in Rabbits when Applied Topically after PRK. Molecular Vision, 20, 1710-1716.
|
[43]
|
Fredman, G. and Serhan, C.N. (2011) Specialized Proresolving Mediator Targets for RvE1 and RvD1 in Peripheral Blood and Mechanisms of Resolution. Biochemical Journal, 437, 185-197. https://doi.org/10.1042/bj20110327
|
[44]
|
Norling, L.V., Spite, M., Yang, R., Flower, R.J., Perretti, M. and Serhan, C.N. (2011) Cutting Edge: Humanized Nano-Proresolving Medicines Mimic Inflammation-Resolution and Enhance Wound Healing. The Journal of Immunology, 186, 5543-5547. https://doi.org/10.4049/jimmunol.1003865
|